Pliant Therapeutics Company Insiders
| PLRX Stock | USD 1.55 0.03 1.90% |
Pliant Therapeutics employs about 171 people. The company is managed by 15 executives with a total tenure of roughly 399 years, averaging almost 26.0 years of service per executive, having 11.4 employees per reported executive. Break down of Pliant Therapeutics' management performance can provide insight into the company performance.
Pliant |
Pliant Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.314) % which means that it has lost $0.314 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5409) %, meaning that it created substantial loss on money invested by shareholders. Pliant Therapeutics' management efficiency ratios could be used to measure how well Pliant Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Pliant Therapeutics Workforce Comparison
Pliant Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 3,709. Pliant Therapeutics holds roughly 171 in number of employees claiming about 5% of equities under Health Care industry.
Pliant Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pliant Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pliant Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pliant Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pliant Therapeutics Notable Stakeholders
A Pliant Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pliant Therapeutics often face trade-offs trying to please all of them. Pliant Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pliant Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Hal MD | Scientific Board | Profile | |
| Mike Ouimette | Gen Sec | Profile | |
| Rik Derynck | Scientific Board | Profile | |
| Dean MD | Scientific Board | Profile | |
| Johannes Hull | Chief Officer | Profile | |
| MBA MD | CEO Pres | Profile | |
| Christopher Keenan | Vice Communications | Profile | |
| MD MBA | Chief Officer | Profile | |
| Lily Cheung | Chief Officer | Profile | |
| ric MD | Chief Officer | Profile | |
| Delphine Imbert | Chief Officer | Profile | |
| Mike JD | General Secretary | Profile | |
| Eric MD | Chief Officer | Profile | |
| Craig Muir | Interim Officer | Profile | |
| Bill DeGrado | Scientific Board | Profile |
About Pliant Therapeutics Management Performance
The success or failure of an entity such as Pliant Therapeutics often depends on how effective the management is. Pliant Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pliant management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pliant management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Pliant Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people.
Please note, the imprecision that can be found in Pliant Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pliant Therapeutics. Check Pliant Therapeutics' Beneish M Score to see the likelihood of Pliant Therapeutics' management manipulating its earnings.
Pliant Therapeutics Workforce Analysis
Traditionally, organizations such as Pliant Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pliant Therapeutics within its industry.Pliant Therapeutics Manpower Efficiency
Return on Pliant Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 14M | |
| Working Capital Per Employee | 1.9M | |
| Working Capital Per Executive | 21.9M |
Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.